← The Wire
VCYTNasdaq
VERACYTE, INC.
Services-Medical Laboratories · DE · CIK 1384101
Develops and distributes in vitro diagnostic tests for global growth
red 8-K · 90d⚡ Elevated coverage
$3.78B
Market cap
$60.19
Last close
-0.5%
1D
+13.2%
5D
1.5M
Volume
Price · last 39 sessions+79.9%
May 4L $32.97 · H $60.49Jun 29
236
Total filings
Jun 11, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteJun 11, 202610-Q10-QMay 6, 20268-KResults of OperationsMay 5, 2026DEFA14ADEFA14AApr 22, 2026DEF 14ADEF 14AApr 22, 20268-KExecutive ChangeMar 16, 202610-K10-KFeb 26, 20268-KResults of OperationsFeb 25, 20268-KResults of OperationsJan 12, 202610-Q10-QNov 5, 20258-KResults of OperationsNov 4, 202510-Q10-QAug 7, 20258-KResults of OperationsAug 6, 20258-KExecutive Change · Shareholder VoteJun 18, 202510-Q10-QMay 8, 20258-KResults of OperationsMay 7, 2025DEFA14ADEFA14AApr 29, 2025DEF 14ADEF 14AApr 29, 202510-K10-KFeb 28, 20258-KResults of OperationsFeb 24, 2025SC 13GSC 13GNov 12, 202410-Q10-QNov 7, 20248-KResults of OperationsNov 6, 20248-KExecutive ChangeSep 4, 202410-Q10-QAug 7, 20248-KResults of OperationsAug 6, 20248-KExecutive Change · Shareholder VoteJun 13, 202410-Q10-QMay 8, 20248-KResults of OperationsMay 7, 2024DEFA14ADEFA14AApr 25, 2024DEF 14ADEF 14AApr 25, 20248-K/ACompany UpdateApr 17, 20248-KCompany UpdateMar 22, 20248-KCompany UpdateFeb 29, 202410-K10-KFeb 29, 20248-KResults of OperationsFeb 22, 20248-KExecutive ChangeFeb 13, 20248-KAcquisition / Disposition · Equity IssuanceFeb 6, 20248-KResults of Operations · Reg FD DisclosureJan 8, 202410-Q10-QNov 8, 20238-KResults of OperationsNov 7, 202310-Q10-QAug 9, 20238-KExecutive Change · Results of OperationsAug 8, 20238-KExecutive Change · Bylaw AmendmentJun 9, 2023DEFA14ADEFA14A CLAWBACK POLICYJun 1, 202310-Q10-QMay 5, 20238-KResults of OperationsMay 4, 2023DEFA14ADEFA14AApr 27, 2023DEF 14ADEF 14AApr 27, 202310-K10-KMar 1, 20238-KResults of OperationsFeb 22, 20238-KBylaw AmendmentFeb 10, 2023SC 13GSC 13GFeb 6, 20238-KExecutive ChangeDec 14, 202210-Q10-QNov 3, 20228-KResults of OperationsNov 2, 20228-KExecutive ChangeAug 11, 202210-Q10-QAug 3, 20228-KResults of OperationsAug 2, 20228-KShareholder VoteJun 16, 202210-Q10-QMay 4, 20228-KResults of OperationsMay 3, 2022DEFA14ADEFA14AApr 26, 2022DEF 14ADEF 14AApr 26, 202210-K10-KFeb 28, 20228-KResults of OperationsFeb 28, 20228-KExecutive ChangeFeb 22, 2022SC 13GSEC SCHEDULE 13GFeb 4, 20228-KExecutive ChangeJan 11, 202210-Q10-QNov 9, 20218-KResults of OperationsNov 9, 20218-KCompany UpdateAug 4, 20218-KAcquisition / Disposition · Equity IssuanceAug 3, 202110-Q10-QJul 29, 20218-KResults of OperationsJul 29, 20218-KExecutive ChangeJul 16, 20218-KMaterial Agreement · Equity IssuanceJul 13, 20218-KExecutive ChangeJul 12, 20218-KExecutive Change · Shareholder VoteJun 8, 20218-K/AMaterial AgreementJun 8, 2021
Insider Activity
In the 90 days to Mar 4, 2026: 6 sold $5.7M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 4, 2026 | Stapley MarcChief Executive Officer | Sell | 26,279 | $36.28 | $953K |
| Mar 4, 2026 | Stapley MarcChief Executive Officer | Sell | 19,244 | $35.56 | $684K |
| Mar 4, 2026 | Chambers RebeccaChief Financial Officer | Sell | 13,941 | $36.33 | $506K |
| Mar 4, 2026 | Leite JohnChief Commercial Officer-CLIA | Sell | 5,260 | $35.19 | $185K |
| Mar 4, 2026 | Mcguire AnnieSVP, General Counsel | Sell | 4,994 | $35.29 | $176K |
| Mar 4, 2026 | Chambers RebeccaChief Financial Officer | Sell | 4,400 | $35.55 | $156K |
| Mar 4, 2026 | Mcguire AnnieSVP, General Counsel | Sell | 1,664 | $36.34 | $60K |
| Mar 2, 2026 | Febbo Phillip G.Chief Scientific & Med Officer | Sell | 13,425 | $36.16 | $485K |
| Dec 16, 2025 | Mcguire AnnieSVP, General Counsel | Sell | 10,639 | $43.13 | $459K |
| Dec 16, 2025 | Mcguire AnnieSVP, General Counsel | Sell | 100 | $43.68 | $4K |
| Dec 5, 2025 | Eastham KarinDirector | Sell | 12,808 | $45.84 | $587K |
| Dec 5, 2025 | Eastham KarinDirector | Sell | 6,392 | $44.52 | $285K |
| Dec 5, 2025 | Eastham KarinDirector | Sell | 800 | $46.59 | $37K |
| Dec 4, 2025 | Chambers RebeccaChief Financial Officer | Sell | 8,537 | $46.61 | $398K |
| Dec 4, 2025 | Chambers RebeccaChief Financial Officer | Sell | 4,741 | $47.25 | $224K |
| Dec 4, 2025 | Stapley MarcChief Executive Officer | Sell | 4,448 | $46.90 | $209K |
| Dec 4, 2025 | Stapley MarcChief Executive Officer | Sell | 3,220 | $47.35 | $152K |
| Dec 4, 2025 | Leite JohnChief Commercial Officer-CLIA | Sell | 1,278 | $47.51 | $61K |
| Dec 4, 2025 | Mcguire AnnieSVP, General Counsel | Sell | 720 | $47.10 | $34K |
| Dec 4, 2025 | Mcguire AnnieSVP, General Counsel | Sell | 702 | $47.51 | $33K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 2 reputable articles.
Investor's Business DailyStock Market Today: Indexes Mixed Before Warsh’s Fed Debut; Veracyte, Google, Lumentum In Focus13d agoInvestor's Business DailyVeracyte CEO Explains How It's Blazing A Trail In Cancer13d agoReutersVeracyte genomic test identifies breast cancer patients who can skip chemo1mo ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance